Cahill Financial Advisors Inc. Increases Position in Novo Nordisk A/S (NYSE:NVO)

Cahill Financial Advisors Inc. boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 7.6% during the third quarter, HoldingsChannel.com reports. The firm owned 4,154 shares of the company’s stock after purchasing an additional 295 shares during the period. Cahill Financial Advisors Inc.’s holdings in Novo Nordisk A/S were worth $495,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Centaurus Financial Inc. lifted its holdings in Novo Nordisk A/S by 53.1% during the third quarter. Centaurus Financial Inc. now owns 10,984 shares of the company’s stock valued at $1,308,000 after purchasing an additional 3,809 shares in the last quarter. Jim Saulnier & Associates LLC purchased a new position in Novo Nordisk A/S in the 3rd quarter valued at about $752,000. Cerity Partners LLC lifted its stake in Novo Nordisk A/S by 29.9% in the 3rd quarter. Cerity Partners LLC now owns 790,636 shares of the company’s stock valued at $94,141,000 after buying an additional 181,933 shares in the last quarter. Nicolet Advisory Services LLC boosted its holdings in Novo Nordisk A/S by 10.7% in the 3rd quarter. Nicolet Advisory Services LLC now owns 3,351 shares of the company’s stock worth $386,000 after buying an additional 323 shares during the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd purchased a new stake in Novo Nordisk A/S during the 3rd quarter worth approximately $714,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 2.4 %

Shares of NVO opened at $105.06 on Monday. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a fifty day simple moving average of $115.48 and a two-hundred day simple moving average of $128.81. The company has a market capitalization of $471.46 billion, a PE ratio of 34.00, a price-to-earnings-growth ratio of 1.35 and a beta of 0.42.

Wall Street Analyst Weigh In

Several brokerages recently commented on NVO. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.